Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)

Date

21 Oct 2023

Session

Poster session 20

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Renaud Descourt

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

R. Descourt1, F. Guisier2, M. Pérol3, J. Cadranel4, M. Duruisseaux5, H. Doubre6, S. Culine7, C. Lamour8, D. Moro-Sibilot9, B. Mennecier10, N. Martin11, O. Bylicki12, C. Chouaid13, L. Greillier14

Author affiliations

  • 1 Oncology, CHRU Brest - Hopital Augustin Morvan, 29200 - Brest/FR
  • 2 Pneumologie, CHU de Rouen Normandie, 76000 - Rouen/FR
  • 3 Medical Oncology Dept., Centre Léon Bérard, 69008 - Lyon/FR
  • 4 Pneumology, Hopital Tenon AP-HP, 75970 - Paris, Cedex/FR
  • 5 Chest Department, Hospices Civiles de Lyon - HCL - Lyon University Hospital Center, 69002 - Lyon/FR
  • 6 Pneumology, Hopital Foch, 92151 - Suresnes/FR
  • 7 Medical Oncology Department, Hopital Saint Louis AP-HP, 75010 - Paris/FR
  • 8 Oncology, CHU Poitiers - Jean Bernard Hôpital, 86021 - Poitiers/FR
  • 9 Thoracic Oncology Department, CHU Grenoble-Alpes - Le site nord à La Tronche - Hopital Michallon, 38700 - La Tronche/FR
  • 10 Pathologie Respiratoire, Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, 67091 - Strasbourg/FR
  • 11 Medical Oncology Department, Centre Anticancer Antoine Lacassagne, 06189 - Nice/FR
  • 12 Pneumology, Hôpital d'Instruction des Armées Sainte Anne Toulon, 83041 - Toulon, Cedex/FR
  • 13 Pneumology, CH Intercommunal de Créteil, 94010 - Créteil/FR
  • 14 Multidisciplinary Oncology And Therapeutic Innovations, Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, 13009 - Marseille/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1369P

Background

Brigatinib and alectinib are both next-generation ALK inhibitors (ALKi) showing efficacy in naïve and post-crizotinib ALK+ advanced non-small-cell lung cancer (aNSCLC). Real-life data on alectinib efficacy after brigatinib failure are missing.

Methods

BrigALK2 study retrospectively assessed the efficacy of brigatinib in 183 ALK + aNSCLC pretreated with at least one ALKi during the brigatinib French Early-Access Program (1 August 2016–21 January 2019). BrigAlec study made a focus on alectinib activity after brigatinib treatment, according to post-brigatinib treatment line in BrigALK2.

Results

92 (50.3%) patients received ≥ 1 agent(s) post-brigatinib. 30 (16.4%) received alectinib: 19 (10.3%) patients were treated with alectinib immediately after brigatinib, 11 (4.9%) following at least one line of treatment. At data cut-off, median follow up was 25.5 (95% CI: 10.6-30.5) months. Median duration of brigatinib treatment (mDOT) and median progression free survival according to investigator (InvmPFS) were 13.6 (95% CI: 6.3-17.7) and 10.9 (95% CI: 6.2-20.2) months, respectively. For patients who received alectinib immediately after brigatinib, mDOT was 7.1 (95% CI: 2.1-18.2) months, mInvPFS, 4.8 (95% CI: 2.0-12.5) months and mOS, 27 (95% CI: 12.5-NR) months from the start of alectinib treatment. Response (RR) and disease control rates (DCR) were 25% and 60%, respectively. Among this subgroup, reasons for brigatinib discontinuation were toxicity and progressive disease for 5 and 14 patients, respectively. mDOT and mPFS were 18.2 (95% CI: 3.4-21.6) and 12.5 (95% CI: 3.3-17.9) months for the former and 5.7 (95% CI: 0.9-10.6) and 3.4 (95% CI: 0.9-9.2) months for the latter, respectively. For patients receiving at least one treatment between brigatinib and alectinib, with a median follow up of 13.3 (95% CI: 2.3-31.5) months, mDOT, mInvPFS and mOS were 11.7 (95% CI: 0.7-21.5), 5.0 (95% CI: 0.5-18.8) and 16 (95% CI: 2.3-NR) months, respectively. RR and DCR were 10 and 30.

Conclusions

According to our retrospective real-life study, alectinib after brigatinib treatment remains an option in metastatic ALK+ NSCLC, especially if brigatinib is discontinued due to toxicity.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

GFPC (Groupe Français de Pneumo-Cancérologie): French Lung Cancer Group.

Funding

Takeda.

Disclosure

R. Descourt: Financial Interests, Personal, Advisory Board: Takeda, AstraZeneca, BMS, Pfizer. F. Guisier: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, BMS, Sanofi, Amgen, MSD; Financial Interests, Institutional, Research Funding: Roche, Pfizer, Takeda. M. Pérol: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, BMS, Lilly, Novartis, Takeda, Gritstone, Sanofi, Pfizer, Amgen, Janssen, Gsk, Eisai, Ipsen; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, BMS, Boehringer Ingelheim, Takeda, Illumina, Pfizer, Medscape; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Takeda, Boehringer Ingelheim; Financial Interests, Personal, Steering Committee Member: Roche; Financial Interests, Personal, Other, DMSB: Roche. J. Cadranel: Financial Interests, Personal, Advisory Board, Participation to boards: Amgen, Daiichi, Takeda, MSD, Jansen, AZ; Financial Interests, Institutional, Other, prospective: AbbVie; Non-Financial Interests, Principal Investigator, Trials: AZ, AbbVie, Takeda, BI, Daiichi, Pfizer, Novartis, Amgen, Sanofi, Jansen, BMS; Financial Interests, Institutional, Research Grant, Translational research: AbbVie; Financial Interests, Institutional, Research Grant, Preclinical research: Sanofi; Financial Interests, Institutional, Research Grant, Support to academic trial: Pfizer; Financial Interests, Personal, Advisory Board, Participation to Boards: Pfizer; Financial Interests, Institutional, Advisory Board, Participation to boards: Novartis, Sanofi; Financial Interests, Personal, Invited Speaker, Participation to boards: BI. M. Duruisseaux: Financial Interests, Personal, Advisory Board: Takeda, Roche, BMS, GSK, Amgen, MSD, Janssen, AstraZeneca, Elevation oncology, Lilly; Financial Interests, Institutional, Research Funding: Lilly. H. Doubre: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Invited Speaker: Léo Pharma; Financial Interests, Institutional, Local PI: BMS, Merck. C. Lamour: Financial Interests, Personal, Advisory Board: Takeda, AstraZeneca, MSD, Sanofi. D. Moro-Sibilot: Financial Interests, Personal, Advisory Board: Lilly, Roche, BMS, MSD, Abbvie, Becton Dickinson, Pfizer, Takeda, AstraZeneca, Boehringer Ingelheim, Novartis, GSK, Sanofi; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Institutional, Funding, IFCT clinical trials: Pfizer; Financial Interests, Institutional, Funding: Roche, Abbvie, AstraZeneca. B. Mennecier: Financial Interests, Personal, Advisory Board: BMS, MSD, AstraZeneca, Sanofi, Pfizer, Lilly, Novartis, Takeda, Boehringer; Financial Interests, Personal, Invited Speaker: Roche. N. Martin: Financial Interests, Personal, Advisory Board: AstraZeneca. O. Bylicki: Financial Interests, Personal, Advisory Board, Expert Board: BMS, Roche, Takeda; Financial Interests, Personal, Advisory Board, Annuel contrat: MSD; Financial Interests, Personal, Advisory Board, expert board: AstraZeneca, Janssen. C. Chouaid: Financial Interests, Personal, Advisory Board: AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen; Financial Interests, Institutional, Funding: AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen. L. Greillier: Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, BMS, MSD, Novartis, Sanofi, Takeda, Roche; Financial Interests, Personal, Invited Speaker: Lilly, Pfizer; Financial Interests, Institutional, Local PI: AstraZeneca, AbbVie, BMS, MSD, Novartis, Takeda, Pfizer, PharmaMar; Financial Interests, Institutional, Coordinating PI: Sanofi; Financial Interests, Personal, Local PI: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.